Cargando…

Clinical validity and clinical utility of Ki67 in early breast cancer

Ki67 represents an immunohistochemical nuclear localized marker that is widely used in surgical pathology. Nuclear immunoreactivity for Ki67 indicates that cells are cycling and are in G1- to S-phase. The percentage of Ki67-positive tumor cells (Ki67 index) therefore provides an estimate of the grow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kreipe, Hans, Harbeck, Nadia, Christgen, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465566/ https://www.ncbi.nlm.nih.gov/pubmed/36105888 http://dx.doi.org/10.1177/17588359221122725

Ejemplares similares

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
por: Nielsen, Torsten O, et al.
Publicado: (2020)

Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group
por: Boyaci, Ceren, et al.
Publicado: (2021)

ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer
por: Grote, Isabel, et al.
Publicado: (2022)

Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
por: Bouzubar, N., et al.
Publicado: (1989)

Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer
por: Davey, Matthew G., et al.
Publicado: (2021)

Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients
por: ALCO, GUL, et al.
Publicado: (2015)

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial
por: Kolberg-Liedtke, Cornelia, et al.
Publicado: (2020)

Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer()()()
por: Surov, Alexey, et al.
Publicado: (2018)

Reliable microRNA profiling in routinely processed formalin-fixed paraffin-embedded breast cancer specimens using fluorescence labelled bead technology
por: Hasemeier, Britta, et al.
Publicado: (2008)

Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
por: Fasanella, S, et al.
Publicado: (2011)

Ki-67 biomarker in breast cancer of Indian women
por: Patil, Amit V., et al.
Publicado: (2011)

Interobserver Variability of Ki-67 Measurement in Breast Cancer
por: Chung, Yul Ri, et al.
Publicado: (2016)

Ki-67, an elusive marker in the prognosis of breast cancer
por: Sood, Neelam
Publicado: (2019)

Association of Ki-67 With Clinicopathological Factors in Breast Cancer
por: ., Nishit, et al.
Publicado: (2021)

Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer
por: Gao, Weiqi, et al.
Publicado: (2019)

Ki67 and breast cancer mortality in women with invasive breast cancer
por: Probert, Jake, et al.
Publicado: (2023)

The intrinsically disorderly story of Ki-67
por: Remnant, Lucy, et al.
Publicado: (2021)

Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
por: Choi, Soon Bo, et al.
Publicado: (2022)

Quantum Dots-Based Quantitative and In Situ Multiple Imaging on Ki67 and Cytokeratin to Improve Ki67 Assessment in Breast Cancer
por: Yuan, Jing Ping, et al.
Publicado: (2015)

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
por: Luporsi, Elisabeth, et al.
Publicado: (2011)

High frequency of lobular breast cancer in distant metastases to the orbit
por: Raap, Mieke, et al.
Publicado: (2015)

Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer.
por: Dettmar, P., et al.
Publicado: (1997)

Expression and Clinical Significance of Ki67 and SOX2 in Colorectal Cancer
por: Hu, Bo, et al.
Publicado: (2023)

A novel model for Ki67 assessment in breast cancer
por: Romero, Quinci, et al.
Publicado: (2014)

Utility of Serum Ki-67 as a Marker for Malignancy in Dogs
por: Estaller, Annkathrin, et al.
Publicado: (2022)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

A comparative study between Ki67 positive versus Ki67 negative females with breast cancer: Cross sectional study
por: Bahaddin, Mowafak Masoud
Publicado: (2020)

Clinical Significance of Ki-67 Labeling Index in Pituitary Macroadenoma
por: Paek, Kyung-Il, et al.
Publicado: (2005)

Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution’s Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer
por: Maranta, Angela Fischer, et al.
Publicado: (2020)

Prognostic Value of Ki67 in Patients with Stage 1–2 Endometrial Cancer: Validation of the Cut-off Value of Ki67 as a Predictive Factor
por: Jiang, Peng, et al.
Publicado: (2020)

Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
por: Varga, Zsuzsanna, et al.
Publicado: (2019)

Optimized Modeling of Metastatic Triple-Negative Invasive Lobular Breast Carcinoma
por: Sflomos, George, et al.
Publicado: (2023)

Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors
por: Christgen, Matthias, et al.
Publicado: (2021)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials
por: Graeser, Monika, et al.
Publicado: (2021)

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C
por: de Gregorio, Amelie, et al.
Publicado: (2022)

Prognostic value of Ki-67 immunolabelling in primary operable breast cancer.
por: Railo, M., et al.
Publicado: (1993)

New Insight into Ki67 Expression at the Invasive Front in Breast Cancer
por: Gong, Peng, et al.
Publicado: (2013)

An Interobserver Reproducibility Analysis of Ki67 Visual Assessment in Breast Cancer
por: Shui, Ruohong, et al.
Publicado: (2015)

Prognostic and predictive value of Ki-67 in triple-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1983b8e54hm8pv98geekipppu0